BioSpace News Archive

Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders advanced into preclinical development

Mirum Pharmaceuticals, Inc. announced that on January 8, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 49,900 shares of common stock to five new employees under Mirum’s 2020 Inducement Plan.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing.

Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 4,095,157 share purchase warrants, all of which are exercisable at $0.50 per share.

VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced the closing of a $150 million Series B financing.